[ Price : $8.95]
Office of Generic Drugs associate director of stakeholder and global engagement Sarah Ibrahim says FDA and EMA are evaluating a ne...[ Price : $8.95]
Gilead Sciences discontinues its Phase 3 ENHANCE-3 study of magrolimab in acute myeloid leukemia (AML) after FDA placed a clinical...[ Price : $8.95]
Federal Register notice: FDA posts a listing of six information collections that have been approved by OMB.[ Price : $8.95]
FDA accepts for priority review a GSK supplemental BLA to extend the indication of its Arexvy adjuvanted respiratory syncytial vir...[ Price : $8.95]
FDA commissioner Robert Califf and two of his top associates describe how the agency uses its role to help address common chronic ...[ Price : $8.95]
Bipartisan members of the House introduce legislation to require FDA to produce a final rule to implement animal testing reforms a...[ Price : $8.95]
FDA grants Orthoson a breakthrough device designation for its Bio-Structural Gel and its use to reduce back pain caused by degener...[ Price : $8.95]
FDA accepts for priority review an Amgen supplemental BLA for Blincyto (blinatumomab) for treating early-stage, CD19-positive B-ce...